| First Author | Mahoney-Crane CL | Year | 2023 |
| Journal | J Neurosci | Volume | 43 |
| Issue | 3 | Pages | 501-521 |
| PubMed ID | 36639889 | Mgi Jnum | J:353369 |
| Mgi Id | MGI:7709589 | Doi | 10.1523/JNEUROSCI.0680-22.2022 |
| Citation | Mahoney-Crane CL, et al. (2023) Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions. J Neurosci 43(3):501-521 |
| abstractText | The most common genetic risk factor for Parkinson's disease (PD) is heterozygous mutations GBA1, which encodes for the lysosomal enzyme, glucocerebrosidase. Reduced glucocerebrosidase activity associates with an accumulation of abnormal alpha-synuclein (alpha-syn) called Lewy pathology, which characterizes PD. PD patients heterozygous for the neuronotypic GBA1L444P mutation (GBA1(+/L444P)) have a 5.6-fold increased risk of cognitive impairments. In this study, we used GBA1(+/L444P) mice of either sex to determine its effects on lipid metabolism, expression of synaptic proteins, behavior, and alpha-syn inclusion formation. At 3 months of age, GBA1(+/L444P) mice demonstrated impaired contextual fear conditioning, and increased motor activity. Hippocampal levels of vGLUT1 were selectively reduced in GBA1(+/L444P) mice. We show, using mass spectrometry, that GBA1L444P expression increased levels of glucosylsphingosine, but not glucosylceramide, in the brains and serum of GBA1(+/L444P) mice. Templated induction of alpha-syn pathology in mice showed an increase in alpha-syn inclusion formation in the hippocampus of GBA1(+/L444P) mice compared with GBA1(+/+) mice, but not in the cortex, or substantia nigra pars compacta. Pathologic alpha-syn reduced SNc dopamine neurons by 50% in both GBA1(+/+) and GBA1(+/L444P) mice. Treatment with a GlcCer synthase inhibitor did not affect abundance of alpha-syn inclusions in the hippocampus or rescue dopamine neuron loss. Overall, these data suggest the importance of evaluating the contribution of elevated glucosylsphingosine to PD phenotypes. Further, our data suggest that expression of neuronotypic GBA1L444P may cause defects in the hippocampus, which may be a mechanism by which cognitive decline is more prevalent in individuals with GBA1-PD.SIGNIFICANCE STATEMENT Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are both pathologically characterized by abnormal alpha-synuclein (alpha-syn). Mutant GBA1 is a risk factor for both PD and DLB. Our data show the expression of neuronotypic GBA1L444P impairs behaviors related to hippocampal function, reduces expression of a hippocampal excitatory synaptic protein, and that the hippocampus is more susceptible to alpha-syn inclusion formation. Further, our data strengthen support for the importance of evaluating the contribution of glucosylsphingosine to PD phenotypes. These outcomes suggest potential mechanisms by which GBA1L444P contributes to the cognitive symptoms clinically observed in PD and DLB. Our findings also highlight the importance of glucosylsphingosine as a relevant biomarker for future therapeutics. |
